Risk factors for breakthrough varicella in healthy children

被引:18
作者
Lim, YJ [1 ]
Chew, FT [1 ]
Tan, AYS [1 ]
Lee, BW [1 ]
机构
[1] Natl Univ Singapore, Dept Paediat, Singapore 119074, Singapore
关键词
varicella; vaccination;
D O I
10.1136/adc.79.6.478
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim-To evaluate the risk factors for breakthrough varicella in a follow up study of a cohort of 181 healthy children immunised when aged 9-24 months with a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka). Design-The children were randomised in a double blind manner into one of four groups to receive one of two production lot vaccine batches, at two different titres thigh titre, 10(3.9) and 10(4.0) plaque forming units (pfu); low titre (heat exposed), 10(2.7) and 10(2.8) pfu). The overall seroconversion rate after immunisation was 99%. Results-One hundred and sixty eight patients were available for review after a mean (SD) follow up of 35 (9) months after vaccination. Multivariate analysis indicated that risk factors for breakthrough varicella were household contact with varicella (adjusted odds ratio (OR), 19.89; 95% confidence interval (CI), 18.39 to 21.39), vaccination age of less than or equal to 14 months (adjusted OR, 2.30; 95% CI, 1.69 to 2.90), and receiving low titre (10(2.7) pfu) vaccine (adjusted OR, 2.13; 95% CI, 1.54 to 2.73). All children who developed breakthrough varicella, had a modified varicella illness, except for three, all of whom had received low titre vaccine. Conclusion-The identification of young immunisation age (less than or equal to 14 months) and low titre vaccine as risk factors for breakthrough varicella have important implications for the implementation of varicella vaccination programmes in healthy children.
引用
收藏
页码:478 / 480
页数:3
相关论文
共 23 条
[1]  
ASANO Y, 1985, PEDIATRICS, V75, P667
[2]  
ASANO Y, 1994, PEDIATRICS, V94, P524
[3]  
ASANO Y, 1996, J INFECT DIS S3, V174, P310
[4]  
BERNSTEIN HH, 1993, PEDIATRICS, V92, P833
[5]   VARICELLA VACCINE [J].
ELLIS, RW .
VACCINE, 1995, 13 (15) :1387-1388
[6]   VARICELLA VACCINE - ITS PAST, PRESENT AND FUTURE [J].
GERSHON, AA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (09) :742-744
[7]  
HALL CB, 1995, PEDIATRICS, V95, P791
[8]   THE INCIDENCE OF ZOSTER AFTER IMMUNIZATION WITH LIVE ATTENUATED VARICELLA VACCINE - A STUDY IN CHILDREN WITH LEUKEMIA [J].
HARDY, I ;
GERSHON, AA ;
STEINBERG, SP ;
LARUSSA, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (22) :1545-1550
[9]   EFFICACY, IMMUNOGENICITY, SAFETY, AND USE OF LIVE ATTENUATED CHICKENPOX VACCINE [J].
KRAUSE, PR ;
KLINMAN, DM .
JOURNAL OF PEDIATRICS, 1995, 127 (04) :518-525
[10]  
LEVENTONKRISS S, 1978, ISRAEL J MED SCI, V14, P766